Dr. Christopher Randolph, PhD, ABPP-CN | Chief Scientific Officer

Dr. Christopher Randolph is Chief Scientific Officer at MedAvante/Prophase and Clinical Professor of Neurology at Loyola University Medical Center. Dr. Randolph has extensive experience in CNS clinical trials work, as an investigator, consultant and creator and supervisor of rater training programs for a large number of Phase II and Phase III multinational studies in Alzheimer’s disease and other neurodegenerative conditions; schizophrenia; stroke; hepatic encephalopathy; and traumatic brain injury.

  • Are Your Raters Undermining Your Alzheimer’s Trials?

    Are Your Raters Undermining Your Alzheimer’s Trials?

    Read Post
  • Homing In On a Moving Target: Meeting the Challenges of Alzheimer’s Disease Research

    Homing In On a Moving Target: Meeting the Challenges of Alzheimer’s Disease Research

    Read Post
  • Identifying Elevated Rates of CDR Scoring Errors

    Identifying Elevated Rates of CDR Scoring Errors

    The goal of this study was to identify a CDR quality metric, based upon internal patterns of domain scores that could be used to identify atypical patterns that might be indicative of scoring errors.

    Read Flipbook
  • Increased Signal Detection in Alzheimer's Disease Clinical Trials

    Increased Signal Detection in Alzheimer's Disease Clinical Trials

    This study investigated the impact of lag time on error rates for commonly used Alzheimer’s disease COAs, as well as the degree to which administration attenuated error rates associated with lag time.

    Read Flipbook
  • RBANS as a Useful Outcome Measure in Prodromal AD Trials

    RBANS as a Useful Outcome Measure in Prodromal AD Trials

    The goal of the present study was to examine the potential utility of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) in prodromal AD trials.

    Read Flipbook
  • Prospective, Head-to-Head Study of Three Computerized Neurocognitive Assessment Tools Part 2: Utility for Assessment of Mild Traumatic Brain

    Prospective, Head-to-Head Study of Three Computerized Neurocognitive Assessment Tools Part 2: Utility for Assessment of Mild Traumatic Brain

    The aim of this study was to evaluate the reliability and validity of three computerized neurocognitive assessment tools (CNTs; i.e., ANAM, DANA, and ImPACT) for assessing mild traumatic brain injury.

    Read Flipbook
  • Acute Clinical Predictors of Symptom Recovery in Emergency Department Patients with Uncomplicated Mild Traumatic Brain Injury or Non-Traumat

    Acute Clinical Predictors of Symptom Recovery in Emergency Department Patients with Uncomplicated Mild Traumatic Brain Injury or Non-Traumat

    The purpose of this study was to investigate the predictors of symptom recovery in a prospective sample of emergency department trauma patients with either mTBI or non-mTBI injuries.

    Read Flipbook
  • Detecting cognitive changes in preclinical Alzheimer’s disease: A review of its feasibility

    Detecting cognitive changes in preclinical Alzheimer’s disease: A review of its feasibility

    Significant progress has been made in characterizing the biological changes occurring in preclinical Alzheimer’s disease (AD).

    Read Flipbook
  • Is cognitive decline measurable in preclinical Alzheimer’s disease?

    Is cognitive decline measurable in preclinical Alzheimer’s disease?

    As Alzheimer’s disease (AD) drug development moves to earlier, preclinical stages of disease, clinicians, trialists, and regulators have wrestled with the question of how to detect cognitive change...

    Read Flipbook
  • A systematic review of potential long-term effects of sport-related concussion

    A systematic review of potential long-term effects of sport-related concussion

    Objective: Systematic review of possible long-term effects of sports-related concussion in retired athletes.

    Read Flipbook
  • Recommended cognitive outcomes in preclinical Alzheimer’s disease - Consensus statement from the European Prevention of Alzheimer’s Dementia

    Recommended cognitive outcomes in preclinical Alzheimer’s disease - Consensus statement from the European Prevention of Alzheimer’s Dementia

    The resulting consensus statement provides recommendations for both future drug trials and research into preclinical Alzheimer’s disease.

    Read Flipbook
  • Multiple comorbid neuropathologies in the setting of Alzheimer’s disease neuropathology and implications for drug development

    Multiple comorbid neuropathologies in the setting of Alzheimer’s disease neuropathology and implications for drug development

    This review will cover the neuropathologic basis of dementia, provide clinical perspectives on multiple pathologies, and discuss therapeutics and biomarkers targeting overlapping pathologies...

    Read Flipbook
  • loading
    Loading More...